The promise of personalized drug dosing moves closer to reality with breakthrough sensor technology that could transform how clinicians monitor medication effectiveness in real time. Current approaches to precision medicine rely on intermittent blood draws and guesswork about how individual patients process drugs, leaving substantial room for dosing errors that can prove deadly with narrow-window medications.
Engineers have developed resilient nanostructured bioelectrodes embedded in microneedles that continuously monitor drug levels through skin for up to six days in living subjects. The devices overcome previous limitations through a bilayer fabrication process featuring micrometer-thick gold adhesion layers and controlled dealloying that creates nanocavity-textured surfaces resistant to tissue abrasion. Testing in freely moving rats demonstrated the sensors accurately track blood-equivalent pharmacokinetic parameters while withstanding mechanical stress from tissue movement.
The technology's clinical potential extends beyond simple drug monitoring to real-time assessment of organ function. In liver-damaged animal models, the sensors detected delayed clearance of the chemotherapy drug irinotecan, while renal studies showed correlation between sensor readings and blood antibiotic concentrations. This represents a significant advance over existing wearable biosensors, which typically suffer from poor sensitivity and short operational lifespans due to biofouling and mechanical failure. The extended monitoring capability could prove particularly valuable for intensive care patients, transplant recipients, and others requiring precise medication management. However, translation to human use will require demonstrating biocompatibility, regulatory approval, and validation across diverse patient populations and drug classes.